Long Pentraxin 3: Experimental and Clinical Relevance in Cardiovascular Diseases

Pentraxin 3 (PTX3) is an essential component of the humoral arm of innate immunity and belongs, together with the C-reactive protein (CRP) and other acute phase proteins, to the pentraxins' superfamily: soluble, multifunctional, pattern recognition proteins. Pentraxins share a common C-terminal...

Full description

Saved in:
Bibliographic Details
Main Authors: Fabrizia Bonacina, Andrea Baragetti, Alberico Luigi Catapano, Giuseppe Danilo Norata
Format: Article
Language:English
Published: Wiley 2013-01-01
Series:Mediators of Inflammation
Online Access:http://dx.doi.org/10.1155/2013/725102
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850232824382095360
author Fabrizia Bonacina
Andrea Baragetti
Alberico Luigi Catapano
Giuseppe Danilo Norata
author_facet Fabrizia Bonacina
Andrea Baragetti
Alberico Luigi Catapano
Giuseppe Danilo Norata
author_sort Fabrizia Bonacina
collection DOAJ
description Pentraxin 3 (PTX3) is an essential component of the humoral arm of innate immunity and belongs, together with the C-reactive protein (CRP) and other acute phase proteins, to the pentraxins' superfamily: soluble, multifunctional, pattern recognition proteins. Pentraxins share a common C-terminal pentraxin domain, which in the case of PTX3 is coupled to an unrelated long N-terminal domain. PTX3 in humans, like CRP, correlates with surrogate markers of atherosclerosis and is independently associated with the risk of developing vascular events. Studies addressing the potential physiopathological role of CRP in the cardiovascular system were so far inconclusive and have been limited by the fact that the sequence and regulation have not been conserved during evolution between mouse and man. On the contrary, the conservation of sequence, gene organization, and regulation of PTX3 supports the translation of animal model findings in humans. While PTX3 deficiency is associated with increased inflammation, cardiac damage, and atherosclerosis, the overexpression limits carotid restenosis after angioplasty. These observations point to a cardiovascular protective effect of PTX3 potentially associated with the ability of tuning inflammation and favor the hypothesis that the increased levels of PTX3 in subjects with cardiovascular diseases may reflect a protective physiological mechanism, which correlates with the immunoinflammatory response observed in several cardiovascular disorders.
format Article
id doaj-art-01eeff3f47314c5c953975699e3b8550
institution OA Journals
issn 0962-9351
1466-1861
language English
publishDate 2013-01-01
publisher Wiley
record_format Article
series Mediators of Inflammation
spelling doaj-art-01eeff3f47314c5c953975699e3b85502025-08-20T02:03:05ZengWileyMediators of Inflammation0962-93511466-18612013-01-01201310.1155/2013/725102725102Long Pentraxin 3: Experimental and Clinical Relevance in Cardiovascular DiseasesFabrizia Bonacina0Andrea Baragetti1Alberico Luigi Catapano2Giuseppe Danilo Norata3Department of Pharmacological and Biomolecular Sciences, Università Degli Studi di Milano, 20133 Milan, ItalyDepartment of Pharmacological and Biomolecular Sciences, Università Degli Studi di Milano, 20133 Milan, ItalyDepartment of Pharmacological and Biomolecular Sciences, Università Degli Studi di Milano, 20133 Milan, ItalyDepartment of Pharmacological and Biomolecular Sciences, Università Degli Studi di Milano, 20133 Milan, ItalyPentraxin 3 (PTX3) is an essential component of the humoral arm of innate immunity and belongs, together with the C-reactive protein (CRP) and other acute phase proteins, to the pentraxins' superfamily: soluble, multifunctional, pattern recognition proteins. Pentraxins share a common C-terminal pentraxin domain, which in the case of PTX3 is coupled to an unrelated long N-terminal domain. PTX3 in humans, like CRP, correlates with surrogate markers of atherosclerosis and is independently associated with the risk of developing vascular events. Studies addressing the potential physiopathological role of CRP in the cardiovascular system were so far inconclusive and have been limited by the fact that the sequence and regulation have not been conserved during evolution between mouse and man. On the contrary, the conservation of sequence, gene organization, and regulation of PTX3 supports the translation of animal model findings in humans. While PTX3 deficiency is associated with increased inflammation, cardiac damage, and atherosclerosis, the overexpression limits carotid restenosis after angioplasty. These observations point to a cardiovascular protective effect of PTX3 potentially associated with the ability of tuning inflammation and favor the hypothesis that the increased levels of PTX3 in subjects with cardiovascular diseases may reflect a protective physiological mechanism, which correlates with the immunoinflammatory response observed in several cardiovascular disorders.http://dx.doi.org/10.1155/2013/725102
spellingShingle Fabrizia Bonacina
Andrea Baragetti
Alberico Luigi Catapano
Giuseppe Danilo Norata
Long Pentraxin 3: Experimental and Clinical Relevance in Cardiovascular Diseases
Mediators of Inflammation
title Long Pentraxin 3: Experimental and Clinical Relevance in Cardiovascular Diseases
title_full Long Pentraxin 3: Experimental and Clinical Relevance in Cardiovascular Diseases
title_fullStr Long Pentraxin 3: Experimental and Clinical Relevance in Cardiovascular Diseases
title_full_unstemmed Long Pentraxin 3: Experimental and Clinical Relevance in Cardiovascular Diseases
title_short Long Pentraxin 3: Experimental and Clinical Relevance in Cardiovascular Diseases
title_sort long pentraxin 3 experimental and clinical relevance in cardiovascular diseases
url http://dx.doi.org/10.1155/2013/725102
work_keys_str_mv AT fabriziabonacina longpentraxin3experimentalandclinicalrelevanceincardiovasculardiseases
AT andreabaragetti longpentraxin3experimentalandclinicalrelevanceincardiovasculardiseases
AT albericoluigicatapano longpentraxin3experimentalandclinicalrelevanceincardiovasculardiseases
AT giuseppedanilonorata longpentraxin3experimentalandclinicalrelevanceincardiovasculardiseases